Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulatorPharmacology Perspective Published on 2024-02-072024-09-05 Journal: Frontiers in Pharmacology [Category] update2024, [키워드] azapeptides CD36 coronavirus Cytokine storm hyper-inflammation macrophages Pneumonia SARS-CoV-2 [DOI] 10.3389/fphar.2024.1303342 PMC 바로가기 [Article Type] Pharmacology Perspective
Anti-COVID-19 potential of Azadirachta indica (Neem) leaf extractReview article Published on 2022-07-012022-10-05 Journal: Scientific African [Category] 신약개발, 임상, [키워드] acute phase acute respiratory syndrome addition Affect age Azadirachta indica benefit binding Brain C-reactive protein cancer cell cardiovascular disease caused chemokines clinical trial Comorbidity complications COVID-19 Cytokine storm Cytokines detectable diabete displacement distress effective Extract extreme favor HIV hyper-inflammation Infection investigated kidney liver Lungs malaria MERS Middle East MODS morbidity and mortality multiple organs nitric oxide obesity organ oxidative stress Population positioned positive Prevent pro-inflammatory Protein reactive oxygen species red blood cell risk factor RNA SARS-CoV SARS-CoV-2 Severe case severe COVID-19 single-stranded syndrome T lymphocytes therapeutic Toxicity turn unique Vascular Vascular endothelium virus yielding [DOI] 10.1016/j.sciaf.2022.e01184 [Article Type] Review article
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19ADAMTS13 희귀 변이의 보균자는 생명을 위협하는 COVID-19의 위험이 높습니다Article Published on 2022-05-292022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] ADAMTS13 Add-on therapy age aggregation Analysis Asymptomatic autosomal dominant autosomal dominant disorder autosomal recessive autosomal recessive disorder binding caplacizumab carrier carriers characterized cleaving Cohort conditioned congenital COVID-19 COVID-19 severity crizanlizumab disintegrin disorder drug enzyme Families GEN-COVID genetic determinant heterozygous state Host hyper-inflammation infections inhibit inhibiting Interaction large vessel leukocyte ligands motif P-selectin Platelet platelet aggregation Prevent recruitment reported SARS-CoV-2 infected subject SARS-COV-2 infection selectin Sex susceptibility thrombocytopenic purpura Thromboembolism thrombosis thrombotic thrombotic microangiopathy Thrombotic thrombocytopenic purpura triggered variant Vascular damage [DOI] 10.3390/v14061185 PMC 바로가기 [Article Type] Article
Potential benefits of ginseng against COVID-19 by targeting inflammasomesReview article Published on 2022-04-012022-10-05 Journal: Journal of Ginseng Research [Category] 변종, 치료제, [키워드] activate acute respiratory syndrome anti-inflammatory effect antiviral immunity benefit cause coronavirus coronavirus disease COVID-19 COVID-19 patients Cytokine storm death determinant evade ginseng Ginsenoside Host hyper-inflammation hyperinflammation immune system impair IMPROVE Inflammasome inflammasome activation inflammatory signaling inhibit multiple organs pathogenic virus Pathways Potential Regulatory Respiratory system Saponin SARS-CoV-2 Symptom therapeutic [DOI] 10.1016/j.jgr.2022.03.008 [Article Type] Review article
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signalingJAK2/STAT3 신호 전달 억제를 통한 코로나19 사이토카인 폭풍 진정Review Published on 2022-02-012022-09-11 Journal: Drug discovery today [Category] 변종, 신약개발, 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral treatment caused clinically evaluated coronavirus COVID-19 COVID-19 mortality COVID-19 pandemic cytokine release Cytokine storm drug Drug discovery effective antiviral treatment herd immunity hyper-inflammation Immunity JAK inhibitor jak inhibitors JAK/STAT signaling JAK2/STAT3 life-threatening lung Lungs New outbreak Pathways Patient reached reported respiratory distress Respiratory failure SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 Signaling STAT syndrome the cytokine storm tissue damage Treatment Vaccines viral variant Viral variants [DOI] 10.1016/j.drudis.2021.10.016 PMC 바로가기 [Article Type] Review
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19중증 COVID-19 환자의 회복기 혈장 치료를 위한 2상 단일 센터 공개 라벨 무작위 대조 시험Clinical Trial Published on 2022-01-192022-09-12 Journal: Nature Communications [Category] SARS, 임상, 진단, 치료기술, 치료법, [키워드] 95% confidence interval adverse effect Adverse reaction all-cause mortality ARDS benefit characterized clinical clinical benefit clinical trial clinical trials Controlled trial convalescent plasma Convalescent plasma therapy COVID-19 disease cytokine Cytokines enrolment Evidence FiO2 General Hospital hazard hyper-inflammation immunization immunological inclusion criteria India Infectious disease Infectious diseases Intervention Kolkata log-rank log-rank test Mantel-Haenszel mechanical ventilation Mild Mild ARDS moderate moderate ARDS Mortality neutralizing antibody not affect not significantly different on mechanical ventilation open label outcome Outcomes research p value PaO2 paO2/fiO2 passive immunization Patient patients patients hospitalized PCR Phase 2 plasma plasma therapy prespecified outcomes Primary outcome Primary outcomes proteome randomised randomised controlled trial Randomized Ratio recruited Registered registry reported response to therapy secondary outcome Secondary outcomes severe COVID-19 severe COVID-19 disease severe COVID-19 patient severe COVID-19 patients single center Standard of care systemic hyper-inflammation the systemic hyper-inflammation therapy treat Treatment treatment arm Trial viral infection Viral RNA was done [DOI] 10.1038/s41467-022-28064-7 PMC 바로가기 [Article Type] Clinical Trial
RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery폐-표적 전달을 위해 메틸 프레드니솔론을 로딩하는 RBC-Hitchhiking 키토산 나노 입자Article Published on 2022-01-012022-08-31 Journal: Journal of controlled release : official journal o [Category] SARS, 치료제, [키워드] accumulation acute lung injury acute respiratory distress acute respiratory distress syndrome AUC cause chitosan Chitosan nanoparticle chronic administration circulation Circulation time cytokine Cytokine storm syndrome Cytokines distribution drug effective erythrocyte erythrocytes facilitated Fluorescein glucocorticoid Glucocorticoids High dose high mortality hitchhiking hyper-inflammation IL-6 in vivo indicated Inflammatory cytokine Inflammatory cytokines Inflammatory response inhibit inhibited injection Interaction leads lipopolysaccharide liver lung Lung injury Lungs Methylprednisolone Methylprednisolone sodium succinate patients with COVID-19 pharmacokinetic plasma concentration RATs RBC-hitchhiking. red blood cell red blood cells reduce respiratory distress Respiratory distress syndrome Side effects significantly significantly higher sodium sodium succinate syndrome tissue TNF-α Treatment treatment groups [DOI] 10.1016/j.jconrel.2021.12.018 PMC 바로가기 [Article Type] Article
Association and predictive value of biomarkers with severe outcomes in hospitalized patients with SARS-CoV-2 infectionSARS-COV-2 감염이있는 입원 환자에서 심각한 결과를 가진 바이오 마커의 연관 및 예측 가치Multicenter Study Published on 2022-01-012022-08-31 Journal: Cytokine [Category] MERS, SARS, 바이오마커, [키워드] Admission Analysis analyzed association Biomarker Biomarkers Blood urea nitrogen Chi-square chi-square tests Coagulation COVID-19 Critical care Cytokines Cytokines and inflammatory mediators D-dimer disease severity Factor frequencies Frequency Growth factors hematological hospitalized patient hyper-inflammation ICU IL-6 IMV in-hospital mortality Inflammation Inflammatory Inflammatory marker inflammatory markers Inflammatory mediators intensive care Invasive mechanical ventilation Kidney function Mann-Whitney U Mechanical mechanical ventilation Mortality multivariable logistic regression Multivariable logistic regression analysis nitrogen outcome outcomes PaO Patient patients hospitalized Platelet Platelet count predict Predictive reduced respiratory Respiratory function risk Risk factors SARS-COV-2 infection suffered the disease urea Ventilation was performed with COVID-19 [DOI] 10.1016/j.cyto.2021.155755 PMC 바로가기 [Article Type] Multicenter Study
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injurySARS-CoV-2 유발 비만 세포 급속 탈과립은 폐포 상피 염증 및 폐 손상을 유발합니다Article Published on 2021-12-172022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 유전자 메커니즘, 치료제, [키워드] ACE-2 ACE2 acute lung injury administration alveolar alveolar epithelial cells binding Cell COVID-19 severity COVID-19 treatments degranulation disrupt epithelial epithelial cells humanized hyper-inflammation hypercytokinemia identifying immune immunomodulator immunomodulators induce Infectious diseases Inflammation initiate initiated Injury lAbel Lung inflammation Lung injury mast cell Mast cells MCs mechanism mediators mice Microbiology mucosa off-label off-label use prevented pro-inflammatory factor pro-inflammatory factors RBD binding reduce regulate rhesus macaques SARS-CoV-2 SARS-COV-2 infection signaling pathway tight junction tight junctions Trigger triggers [DOI] 10.1038/s41392-021-00849-0 PMC 바로가기 [Article Type] Article
Hemophagocytosis, hyper-inflammatory responses, and multiple organ damages in COVID-19-associated hyperferritinemiaClinical Trial Published on 2021-12-042022-10-04 Journal: Annals of Hematology [Category] MERS, SARS, 임상, [키워드] 95% CI age Analysis ARDS AUROC Characteristics chronic pulmonary disease COVID-19 COVID-19 patients cut-off value D-dimer death described Fever hemophagocytic lymphohistiocytosis hsCRP hyper-inflammation Hyper-inflammatory responses Hyperferritinemia IL-6 In-hospital death in-hospital mortality independent predictor indicated mechanical ventilator median much higher Multiple organ damage organ dysfunction Patient patients with AKI Prevalence Prognosis progressed proportion Retrospective study supplementary material Support [DOI] 10.1007/s00277-021-04735-1 PMC 바로가기 [Article Type] Clinical Trial